Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Diabetes

Free Subscription Articles published in J Am Soc Nephrol Retrieve available abstracts of 41 articles: HTML format

Single Articles

April 2026
1. MOTTL A, Scott C, Green JB, Heerspink HJL, et al
   Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
   J Am Soc Nephrol. 2026;37:764-776.
   PubMed     Abstract available
   
   
   March 2026
2. LEVIN-IAINA N, Reiner-Benaim A, Abu-Akel S, Habashi N, et al
   Authors' Reply: Gestational Diabetes as a Window into Underdocumented CKD in Women.
   J Am Soc Nephrol. 2026 Mar 19. doi: 10.1681/ASN.0000001064.
   PubMed    
   
   
   
3. DONG J, Shi S
   Gestational Diabetes as a Window into Underdocumented CKD in Women.
   J Am Soc Nephrol. 2026 Mar 19. doi: 10.1681/ASN.0000001063.
   PubMed    
   
   
   
4. HU H, Liang W, Ding G
   Podocyte Metabolic Reprogramming and Targeted Therapy.
   J Am Soc Nephrol. 2026;37:619-633.
   PubMed     Abstract available
   
   
   January 2026
5. LEVIN-IAINA N, Reiner-Benaim A, Abu-Akel S, Habashi N, et al
   Clinical Implications of Missed CKD Diagnosis in Adults with and without Diabetes Mellitus.
   J Am Soc Nephrol. 2026 Jan 14. doi: 10.1681/ASN.0000001005.
   PubMed     Abstract available
   
   
   
6. BALZER MS, Zhou J, Abedini A, Ma Z, et al
   Single-Cell Resolution Drug Effects of Renin-Angiotensin-Aldosterone Blockade in ZSF1 Rat Diabetic Kidney Disease.
   J Am Soc Nephrol. 2026 Jan 7. doi: 10.1681/ASN.0000000995.
   PubMed     Abstract available
   
   
   
7. CHEN SC, Lee YT
   Proteomic CKD Prediction in Type 2 Diabetes: Underexplored Limitations and Translational Gaps.
   J Am Soc Nephrol. 2026 Jan 6. doi: 10.1681/ASN.0000000991.
   PubMed    
   
   
   
8. CHEUNG CY, Lee CH, Lam KS, Xu A, et al
   Authors' Reply: Proteomic CKD Prediction in Type 2 Diabetes: Underexplored Limitations and Translational Gaps.
   J Am Soc Nephrol. 2026 Jan 6. doi: 10.1681/ASN.0000000992.
   PubMed    
   
   
   December 2025
9. HOFHERR A, Maki-Petaja K, Selvarajah V, Grice D, et al
   Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial.
   J Am Soc Nephrol. 2025 Dec 5. doi: 10.1681/ASN.0000000966.
   PubMed    
   
   
   November 2025
10. MATSOUKAS C, Tomic TT, Tonelius P, Nunez-Duran E, et al
    Streamlining the Histopathological Workflow in Diabetic Kidney Disease with Artificial Intelligence.
    J Am Soc Nephrol. 2025 Nov 12. doi: 10.1681/ASN.0000000923.
    PubMed     Abstract available
    
    
    October 2025
11. XU C, Cheung CY, Zhong J, Lin Y, et al
    A Five-Plasma Protein-Based Algorithm for Predicting Incident CKD in Type 2 Diabetes.
    J Am Soc Nephrol. 2025 Oct 20. doi: 10.1681/ASN.0000000902.
    PubMed    
    
    
    
12. SRIDHAR VS, Odutayo A, Davies MJ, Cherney DZI, et al
    Authors' Reply: Further Considerations on the Clinical Evaluation of Sotagliflozin in Type 1 Diabetes with CKD.
    J Am Soc Nephrol. 2025 Oct 10. doi: 10.1681/ASN.0000000868.
    PubMed    
    
    
    
13. WANG R, Xie J, Wang M
    Further Considerations on the Clinical Evaluation of Sotagliflozin in Type 1 Diabetes with CKD.
    J Am Soc Nephrol. 2025 Oct 10. doi: 10.1681/ASN.0000000867.
    PubMed    
    
    
    September 2025
14. RHEE CM, Allon M, Mehrotra R
    Commemorating the National Institute of Diabetes and Digestive and Kidney Diseases' Advances in Kidney Health: 75 Years of Discovery and Impact.
    J Am Soc Nephrol. 2025 Sep 30. doi: 10.1681/ASN.0000000898.
    PubMed     Abstract available
    
    
    
15. FERREIRA JP, Mendonca L, Marques P, Neves JS, et al
    Albuminuria Is the Key Driver of Kidney Benefit with Aldosterone Receptor Antagonists in Type 2 Diabetes.
    J Am Soc Nephrol. 2025 Sep 2. doi: 10.1681/ASN.0000000877.
    PubMed    
    
    
    June 2025
16. HANNEDOUCHE T
    Acetazolamide and Glomerular Hyperfiltration in Type 1 Diabetes: Additional Insights from Early Clinical Research.
    J Am Soc Nephrol. 2025 Jun 23. doi: 10.1681/ASN.0000000780.
    PubMed    
    
    
    
17. HEERSPINK HJL, Friedman AN, Bjornstad P, van Raalte DH, et al
    Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.
    J Am Soc Nephrol. 2025 Jun 13. doi: 10.1681/ASN.0000000764.
    PubMed     Abstract available
    
    
    May 2025
18. KRISHNA PATEL HA, Wang J, Zinn CJ, Learmonth M, et al
    Fortifying the Diabetic Kidney Disease Treatment Armamentarium: Multitarget Senotherapeutic and Regenerative Strategies.
    J Am Soc Nephrol. 2025 May 7. doi: 10.1681/ASN.0000000754.
    PubMed    
    
    
    
19. RASHID AM, Khan MS, Cherney DZI, Mehta A, et al
    Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes.
    J Am Soc Nephrol. 2025 May 6. doi: 10.1681/ASN.0000000752.
    PubMed     Abstract available
    
    
    
20. COLE JB, Dahlstrom EH, Fermin D, Gupta Y, et al
    Genome-Wide Association Study of Quantitative Kidney Function in 52,531 Individuals with Diabetes Identifies Five Diabetes-Specific Loci.
    J Am Soc Nephrol. 2025 May 5. doi: 10.1681/ASN.0000000718.
    PubMed     Abstract available
    
    
    March 2025
21. LI XQ, Zhang JX, Li L, Wu QY, et al
    Deficiency of GADD45alpha-R-Loop Pathway and Kidney Injury in Diabetic Nephropathy.
    J Am Soc Nephrol. 2025 Mar 18. doi: 10.1681/ASN.0000000681.
    PubMed     Abstract available
    
    
    
22. ABE M, Niioka H, Matsumoto A, Katsuma Y, et al
    Self-Supervised Learning for Feature Extraction from Glomerular Images and Disease Classification with Minimal Annotations.
    J Am Soc Nephrol. 2025;36:471-486.
    PubMed     Abstract available
    
    
    February 2025
23. SRIDHAR VS, Kugathasan L, Lovblom LE, Huajing N, et al
    Indexing GFR Using Extracellular Volume versus Body Surface Area in a Population with Type 1 Diabetes and DKD.
    J Am Soc Nephrol. 2025 Feb 21. doi: 10.1681/ASN.0000000668.
    PubMed    
    
    
    
24. LI W, Zhang Z, Peng Z, Hu H, et al
    PIEZO1-Mediated Calcium Signaling and Podocyte Injury in Diabetic Kidney Disease.
    J Am Soc Nephrol. 2025 Feb 11. doi: 10.1681/ASN.0000000634.
    PubMed     Abstract available
    
    
    January 2025
25. COCA SG, Nadkarni GN
    KidneyintelX.dkd: An Innovation in Precision Medicine for Diabetic Kidney Disease.
    J Am Soc Nephrol. 2025 Jan 30. doi: 10.1681/ASN.0000000644.
    PubMed    
    
    
    
26. BORG R, Cherney DZ
    Glomerular Hyperfiltration and Tubuloglomerular Feedback in Diabetic Kidney Disease: Physiological Insights and Potential Clinical Translation.
    J Am Soc Nephrol. 2025 Jan 22. doi: 10.1681/ASN.0000000615.
    PubMed    
    
    
    
27. TANG M, Morieri ML, Kalim S, Doria A, et al
    Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
    J Am Soc Nephrol. 2025 Jan 7. doi: 10.1681/ASN.0000000620.
    PubMed    
    
    
    November 2024
28. MEHTA SS, Surapaneni AL, Pandit K, Xu Y, et al
    Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Prescriptions in Type 2 Diabetes by Kidney and Cardiovascular Disease.
    J Am Soc Nephrol. 2024 Nov 27. doi: 10.1681/ASN.0000000585.
    PubMed    
    
    
    
29. SRIDHAR VS, Odutayo A, Garg S, Danne T, et al
    Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD.
    J Am Soc Nephrol. 2024 Nov 1. doi: 10.1681/ASN.0000000540.
    PubMed     Abstract available
    
    
    October 2024
30. MIN L, Chen Y, Liu R, Li Z, et al
    Targeting KLF2 as a Novel Therapy for Glomerular Endothelial Cell Injury in Diabetic Kidney Disease.
    J Am Soc Nephrol. 2024 Oct 9. doi: 10.1681/ASN.0000000000000498.
    PubMed     Abstract available
    
    
    
31. GINSBERG C, Seegmiller JC, Vallon V, SeungMi Jin S, et al
    Acetazolamide Therapy and Kidney Function in Persons with Non-albuminuric Diabetes Mellitus Type 1.
    J Am Soc Nephrol. 2024 Oct 8. doi: 10.1681/ASN.0000000515.
    PubMed     Abstract available
    
    
    
32. BAKKER WM, Gansevoort RT, Yang C, Chertow GM, et al
    Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients with CKD.
    J Am Soc Nephrol. 2024;35:1446-1449.
    PubMed    
    
    
    September 2024
33. TOUYZ RM
    Learning from Negative Trials for Diabetic Kidney Disease.
    J Am Soc Nephrol. 2024 Sep 26. doi: 10.1681/ASN.0000000511.
    PubMed    
    
    
    August 2024
34. COOPER M, Cherney DZI, Greene TH, Heerspink HJL, et al
    Vascular Endothelial Growth Factor (VEGF)-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial.
    J Am Soc Nephrol. 2024 Aug 16. doi: 10.1681/ASN.0000000000000438.
    PubMed     Abstract available
    
    
    July 2024
35. THOMAS RL, Rifkin DE
    Renal Reinforcements: Slowing Diabetic Kidney Disease with Multiple New Agents.
    J Am Soc Nephrol. 2024 Jul 30. doi: 10.1681/ASN.0000000000000458.
    PubMed    
    
    
    
36. HEERSPINK HJL, Perkovic V, Tuttle KR, Pergola PE, et al
    Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.
    J Am Soc Nephrol. 2024 Jul 17. doi: 10.1681/ASN.0000000000000444.
    PubMed     Abstract available
    
    
    May 2024
37. VELICKOVIC D, Shapiro JP, Parikh SV, Rovin B, et al
    Protein N-glycans in Healthy and Sclerotic Glomeruli in Diabetic Kidney Disease.
    J Am Soc Nephrol. 2024 May 21. doi: 10.1681/ASN.0000000000000393.
    PubMed     Abstract available
    
    
    
38. DOKE T, Bjornstad P
    Endothelial-Mesenchymal Transition Switch and Diabetic Kidney Disease.
    J Am Soc Nephrol. 2024 May 3. doi: 10.1681/ASN.0000000000000364.
    PubMed    
    
    
    April 2024
39. MAXWELL S, Okabe J, Kaipananickal H, Rodriguez H, et al
    Set7 Methyltransferase and Phenotypic Switch in Diabetic Glomerular Endothelial Cells.
    J Am Soc Nephrol. 2024 Apr 17. doi: 10.1681/ASN.0000000000000345.
    PubMed     Abstract available
    
    
    
40. ISAKSSON GL, Hinrichs GR, Andersen H, Bach ML, et al
    Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria.
    J Am Soc Nephrol. 2024;35:410-425.
    PubMed     Abstract available
    
    
    January 2024
41. FWU CW, Eggers PW, Norton JM, Gipson DS, et al
    Age- and Race-Specific Changes in End Stage Kidney Disease Incidence over Four Decades.
    J Am Soc Nephrol. 2024 Jan 30. doi: 10.1681/ASN.0000000000000310.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum